Aravive to Host Key Opinion Leader Symposium on May 11, 2022
05 mai 2022 07h00 HE
|
Aravive, Inc.
HOUSTON, May 05, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced that it...
Aravive Announces Poster Presentations at the 2022 ASCO Annual Meeting
29 avr. 2022 07h00 HE
|
Aravive, Inc.
HOUSTON, April 29, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the...
Aravive Announces Closing of $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
01 avr. 2022 07h00 HE
|
Aravive, Inc.
HOUSTON, April 01, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, announced that it has...
Aravive Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Updates
31 mars 2022 16h05 HE
|
Aravive, Inc.
Reported positive data from Phase 1b trials of batiraxcept in clear cell renal cell carcinoma and pancreatic adenocarcinoma in 1Q’22; on track to report updated data in 2Q’22Dosed first patient in...
Aravive Announces $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
30 mars 2022 08h00 HE
|
Aravive, Inc.
HOUSTON, March 30, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, announced today that it...
Aravive Appoints Scott Dove, Ph.D., as Chief Operating Officer
22 mars 2022 07h00 HE
|
Aravive, Inc.
HOUSTON, March 22, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the...
Aravive to Participate In-Person at 34th Annual ROTH Conference
07 mars 2022 07h00 HE
|
Aravive, Inc.
HOUSTON, March 07, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, announced that Gail...
Aravive Announces Positive Updated Data and New Biomarker Data from Phase 1b Study of Batiraxcept in Clear Cell Renal Cell Carcinoma
03 mars 2022 07h00 HE
|
Aravive, Inc.
46% Best Overall Response Rate in the ITT Population 63% Best Overall Response Rate in the sAXL/GAS6 Biomarker High Population 6-month Progression-Free Survival Rate in the ITT Population of 79%...
Aravive to Present Updated Modeling Data from Batiraxcept Clinical Trials at the AACR Annual Meeting
02 mars 2022 07h00 HE
|
Aravive, Inc.
HOUSTON, March 02, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, will present updated...
Aravive Announces First Patient Dosed in Phase 2 Study of Batiraxcept in Clear Cell Renal Cell Carcinoma
31 janv. 2022 07h00 HE
|
Aravive, Inc.
HOUSTON, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced that the...